Open AccessThis article is
- freely available
Marine Antitumor Drugs: Status, Shortfalls and Strategies
Department of Chemistry, Pukyong National University, Busan 608-737, Korea
Marine Bioprocess Research Center, Pukyong National University, Busan 608-737, Korea
* Author to whom correspondence should be addressed.
Received: 31 August 2010; in revised form: 17 September 2010 / Accepted: 13 October 2010 / Published: 15 October 2010
Abstract: Cancer is considered as one of the deadliest diseases in the medical field. Apart from the preventive therapies, it is important to find a curative measure which holds no loopholes and acts accurately and precisely to curb cancer. Over the past few decades, there have been advances in this field and there are many antitumor compounds available on the market, which are of natural as well as synthetic origin. Marine chemotherapy is well recognized nowadays and profound development has been achieved by researchers to deal with different molecular pathways of tumors. However, the marine environment has been less explored for the production of safe and novel antitumor compounds. The reason is a number of shortfalls in this field. Though ample reviews cover the importance and applications of various anticancerous compounds from marine natural products, in the present review, we have tried to bring the current status of antitumor research based on marine inhibitors of cancer signaling pathways. In addition, focus has been placed on the shortfalls and probable strategies in the arena of marine antitumor drug discovery.
Keywords: marine antitumor compounds; cancer signaling pathways; shortfalls in cancer research; clinical status of antitumor drugs
Citations to this Article
Cite This Article
MDPI and ACS Style
Bhatnagar, I.; Kim, S.-K. Marine Antitumor Drugs: Status, Shortfalls and Strategies. Mar. Drugs 2010, 8, 2702-2720.
Bhatnagar I, Kim S-K. Marine Antitumor Drugs: Status, Shortfalls and Strategies. Marine Drugs. 2010; 8(10):2702-2720.
Bhatnagar, Ira; Kim, Se-Kwon. 2010. "Marine Antitumor Drugs: Status, Shortfalls and Strategies." Mar. Drugs 8, no. 10: 2702-2720.